1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
604C3E48142885082002586BD003DB404
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/04C3E48142885082002586BD003DB404?OpenDocument
18
19OpenDocument
203.226.72.118
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB






Products & Services >> Best Practice Database >>Archived Research Alerts >>March 2021 Research

MARCH 2021 Research Alert

This month we added six new studies to the Best Practice Database, the research repository for Best Practices, LLC. This month's new studies include three on the topic of disease awareness programs and three new case studies on timely topics. The first case study is about the successful digital launch of Nurtec, Biohaven's new migraine drug; the second is a meta-analysis of new product bridge patient assistance programs; and the third case study examines field staffing levels for Skyrizi's launch. The final three studies all involve disease awareness programs and they explore key aspects of these important programs, including structure and timing; budget and effectiveness; and advocacy groups/social media utilization.

The new Best Practices, LLC studies listed below under Newly Added Research explore how leading companies have made their operations more effective across these different areas.


Download: Pure Play Digital Launch: How Biohaven met the Challenge of a Global Pandemic to Launch Nurtec, a new Blockbuster Migraine Drug (5665)

This Best Practices, LLC case study examines Nurtec’s pure play digital launch; it probes how Biohaven embraced new technology, digital education, and digital messaging approaches to support one of the industry's first and most successful all-digital launches.


Download: Benchmarking Meta-Analysis of New Product Bridge and Fast Start Patient Assistance Programs (5668)

This research identifies and spotlights current trends and future directions of bridge assistance and fast start programs supporting new biopharmaceutical product programs.


Download: Skyrizi Case Analysis: Summoning the Right Sales Resources to Support a New Blockbuster's Launch (5669)

This analysis probes what AbbVie invested in terms of staff FTEs to cover medical and field sales operations for this new immunology drug with dermatology indications and blockbuster potential.


Download: Disease Awareness Program Excellence: Structure and Timing (5670)

The Best Practices, LLC study presents an array of insights and benchmarks around the structure, timing, and activities for disease awareness programs.


Download: Disease Awareness Program Excellence: Budget and Effectiveness (5671)

This research contains insights, best practices, and pitfalls that leading biopharma organizations have learned from their recent disease awareness campaigns.


Download: Disease Awareness Program Excellence: Utilizing Advocacy Groups and Social Media (5672)

Best Practices, LLC conducted this benchmarking research to spotlight effective practices around the utilization of advocacy groups and social media for disease awareness programs.